The gut microbiota, identified as the target for vegetables, can affect the development of obesity and associated metabolic syndromes. As a medicinal and edible plant, Luffa cylindrica (L.) Roem (LC) has abundant nutrients that can effectively reduce obesity risk. However, the interaction between the prevention effects of LC against obesity and the modulating gut microbiota of LC remain obscure. This study demonstrated LC supplementation improved high-fat diet (HFD)-induced gut microbiota dysbiosis and significantly enhanced short-chain fatty acid (SCFA)-producing bacteria (e.g., Blautia) along with SCFA content accumulation in the gut. Meanwhile, LC supplementation substantially restored gut barrier damage in long-term HFD treatment. Moreover, LC supplementation improved HFD-induced overweight, hyperlipidemia, insulin resistance, and chronic inflammation. Gene expression profiles showed that LC displayed an important impact on hepatic lipid transport and lipid synthesis (sterol regulatory element binding transcriptional factor 1c-peroxisome proliferator-activated receptor g signaling pathway). More importantly, an antibiotic treatment experiment demonstrated that the beneficial effects of LC in reducing obesity risk largely depended on the gut microbiota, especially SCFA-producing bacteria (e.g., Blautia). Therefore, LC supplementation improved gut microbiota dysbiosis via enhancing SCFA-producing bacteria (e.g., Blautia), maintained gut barrier integrity, and alleviated the development of obesity. Overall, LC would provide a potential dietary intervention strategy against obesity and enteral homeostasis dysbiosis through modulating the gut microbiota.-Zhang, L., Shi, M., Ji, J., Hu, X., Chen, F. Gut microbiota determines the prevention effects of Luffa cylindrica (L.) Roem supplementation against obesity and associated metabolic disorders induced by high-fat diet. FASEB J. 33, 10339-10352 (2019). www.fasebj.org
and even amino acid metabolism in crucial signaling pathways (11) (12) (13) .
The gut microbiota, as one of the most critical environmental factors, has been clarified to sufficiently participate in the various metabolisms of their host. Much evidence suggests that the alteration of the gut microbiota community is closely bound up with lipid metabolism, glucose metabolism, amino acid metabolism, insulin resistance, energy metabolism, and the immune system (14, 15) . Genetic or nutritional obesity presented a higher abundance of Firmicutes and a lower abundance of Bacteroidetes on phylum level in gut microbiota composition (16) (17) (18) . The intestine microbiota from obese individuals can contribute to body weight gain and fat accumulation in mice recipients fed a low-fat diet by fecal transplantation methods (19) . A growing number of studies indicate that the gut microbiota could make deep influences on the host physiologic metabolism (20) (21) (22) . As end products of carbohydrates fermented by the gut microbiome, short-chain fatty acids (SCFAs) have been identified to be involved in improving host metabolic syndromes (23) . Plenty of dietary fibers or phytochemicals in fruits and vegetables have been demonstrated to selectively boost beneficial microbiota growth (such as SCFAproducing bacteria) (23) and suppress harmful bacteria translocation (such as LPS-producing bacteria) (24) , thereby maintaining host physiologic homeostasis (25) (26) (27) .
Luffa cylindrica (L.) Roem (LC), which belongs to the family cucurbitaceae, is popular as a daily vegetable and is cultivated worldwide. Bioactive components analysis shows LC is rich in dietary fiber, vitamins, polyphenols, flavonoids, saponin, triterpenoids, oleanolic acid, carotenoids, chlorophylls, and other nutrients (28, 29) . Previous works demonstrated that the whole fruit of LC could be used as folk medicine for treating cough, fever, dyspnea, and subcutaneous swelling (30) . Moreover, LC extracts played anticancer, antitoxicity, and anti-inflammation roles in vitro (31, 32) . Although these studies suggest LC contains more natural phytochemical compounds that effectively benefit human health, whether the gut microbiota determines the improvement roles of LC is less known and still needs to be discovered.
In the present work, we demonstrate that freezedried whole-fruit LC supplementation definitely relieves high-fat diet (HFD)-induced gut microbiota dysbiosis, promotes the abundance of SCFA-producing bacteria (e.g., Blautia), and maintains intestinal barrier integrity. Moreover, LC supplementation effectively alleviates obesity and associated metabolic syndromes (insulin resistance and low-grade inflammation) in obese mice and regulates abnormal lipid metabolism on the transcriptional level. More importantly, antibiotic treatment for inhibiting the gut microbiota deprives of the main antiobesity effects of LC. Our findings suggest that LC supplementation may be helpful for preventing metabolic disturbance induced by HFD via improving intestinal microbiome dysbiosis.
MATERIALS AND METHODS

Animal diets
Fresh whole fruit of LC (bang si gua variety) was freeze-dried and utilized at the dose of 2 g/kg body weight for animal studies. Basic nutritional compositions of freeze-dried LC were analyzed and listed in Supplemental Table S1 . Normal control diet (NCD) (D12450B, 10% fat; 3.85 kcal/g) and HFD (D12492, 60% fat; 5.24 kcal/g) were purchased from Research Diets (New Brunswick, NJ, USA).
Animal studies
Male 5-wk-old C57BL/6J mice were purchased from Beijing Vital River Laboratory Animal Technology (Beijing, China) and housed in specific pathogen-free room at controlled-temperature (22-24°C), 12-h light/dark cycle, 4-5 mice per cage, with food and water ad libitum. The study protocols were approved by the Animal Care Committee of China Agricultural University and conformed to the Guide for the Care and Use of Laboratory Animals [National Institutes of Health (NIH), Bethesda, MD, USA].
With 1 wk of acclimatization, mice were randomly divided into 4 groups containing 12-15 mice per group and were fed with NCD or HFD for 14 wks, respectively. Meanwhile, the treatment groups [NCD+L group (fed NCD and LC supplementation) and HFD+L group (fed HFD and LC supplementation)] were administrated with LC supplementation by intragastric gavage at the dose of 2 g/kg body weight, and other control groups (NCD group and HFD group) were orally administrated with the equal volume of saline.
For mice in the antibiotic treatment experiment, male 5wk-old C57BL/6J mice were treated with antibiotic mixture containing ampicillin and neomycin (AN) (1 mg/ml ampicillin and 0.5 mg/ml neomycin) in drinking water for 3 d and then randomly distributed into 2 groups (HFD+AN group and HFD+AN+L group, 12-15 mice per group) fed with HFD in presence or absence of LC (2 g/kg body weight) by intragastric gavage, respectively. The drinking water with AN was changed every 3 d and lasted for 10 wks.
In all the animal studies, body weight and diet intake were measured every week. At the end of the experiments, all the mice were euthanized after 12 h starvation. The blood was obtained from the orbital vascular plexus, and the serum was isolated at 1000 rpm for 10 min. The tissues were weighted, frozen in liquid nitrogen immediately, and kept at 280°C until the subsequent analysis.
Glucose and insulin tolerance tests
During the final 2 wk, mice (n = 12/group) were randomly selected, starved for 10 h, and administered an intraperitoneal glucose tolerance test (IGTT) using glucose at a dose of 2 g/kg body weight. The mice (n = 12/group) were randomly selected, starved for 6 h, and administrated an insulin tolerance test (ITT) by intraperitoneal injection using human insulin (Novolin R; Novo Nordisk, Bagsvaerd, Denmark) at a dose of 0.75 IU/kg body weight. For IGTT and ITT, blood glucose was measured at 0, 15, 30, 60, 90, and 120 min using an Accu-Chek Active glucometer (Roche, Basel, Switzerland).
Harvard Apparatus, Barcelona, Spain), and acclimated for 24 h. Then, oxygen consumption as well as carbon dioxide production for each mouse were recorded every 10 min in the following 24 h, and energy expenditure (EE) was calculated.
Biochemical analysis
The samples in this assay were randomly selected in each group (n = 8/group). The levels of glucose, total triglyceride (TG), and total cholesterol (TC) in serum were detected using automatic biochemical analyzer (3100; Hitachi, Tokyo, Japan). The levels of insulin and free fatty acids in serum (n = 8/group) were measured using commercial kits (Beijing Sino-UK Institute of Biologic Technology, Beijing, China). TG and TC contents in liver and feces (n = 8/group) were extracted and measured using a commercial kit according to the manufacturer's instruction (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).
Histologic analysis
The epididymal (Epi) white adipose tissue (WAT), liver, jejunum, and colon (n = 6-8 per group) were randomly selected in each group for histologic analysis. Segments of the tissues were fixed in 10% formalin, embedded in paraffin, sectioned into 5-mm-thick slices, and stained with hematoxylin and eosin (H&E) or alcian blue periodic acid schiff (AB-PAS). Frozen liver sections were stained with Oil Red O. All the processed slices were examined using a Zeiss microscope (Axio Observer A1; Carl Zeiss, Oberkochen, Germany). Adipocyte sizes, small intestinal villi length, and mucus layer thickness were measured using ImageJ software (NIH).
In vitro fermentation studies
Simulated gastric fluid, small intestinal fluid, and fermentation medium from HFD-fed mice were prepared as described by Ding et al. (33) . For fecal inoculum preparation, fresh feces from HFD-fed mice were collected and diluted into 10% using PBS buffer. After being vortexed thoroughly, the fecal inoculums were isolated from homogenized mixture after centrifuging at 3000 rpm for 5 min to remove the impurities. LC powder (1 g) was added into 5 ml simulated gastric fluid for shaking at 120 rpm for 1.5 h at 37°C, which was then transferred into the same volume of simulated small intestinal fluid for shaking at 120 rpm for 1.5 h at 37°C. Subsequently, 10 ml of the digestion fluid was mixed thoroughly with 60 ml fermentation medium and 30 ml fecal inoculums and incubated in anaerobic chamber at 37°C. The fermented samples were collected at 0 and 10 h for genomic DNA (gDNA) isolation to detect the abundances of bacteria.
Gene expression analysis
The samples in this assay were randomly selected from each group (n = 8-9 per group). Total RNA in tissues was isolated using Trizol reagent (Thermo Fisher Scientific, Waltham, MA, USA) and synthesized into cDNA using PrimeScript RT Reagent Kit with gDNA Eraser (Takara Bio, Kyoto, Japan). Real-time quantitative RT-PCR (qRT-PCR) analysis was performed in a 384-well plate using LightCycler 480 system (Roche) with SYBR Premix Ex Taq (Takara Bio) as described by Zhang et al. (34) . Glyceraldehyde 3-phosphate dehydrogenase was selected as a reference gene, and relative expression was normalized using the 2 2DDCt method. Mean expression of target genes in NCD group was set as 1. The primers used are listed in Supplemental Table  S2 , and the assay was performed in triplicate.
To detect the abundance of certain gut bacteria, a specific sequence was amplified from fecal bacteria gDNA using Pri-meStar Max DNA Polymerase (Takara Bio) and then cloned into the vector pMD19-T (Takara Bio) to construct the standard plasmid. Bacterial gDNA (n = 6/group) was isolated from feces or fermented samples using TiaNamp Stool DNA kit (Tiangen Biotech, Beijing, China). The standard curve was made by 10-fold serial dilutions of standard plasmid. A total of 10 ng of diluted gDNA in each sample was detected in a total volume of 10 ml reaction system containing a 0.25-mm concentration of each specific primer and 5 ml SYBR Premix Ex Taq. Amplification procedure was run according to the manufacturer's instruction. Copy abundance of bacteria was calculated with DDCt by the standard curve. The primers used are provided in Supplemental  Table S2 , and the assay was performed in triplicate.
Bacterial fermentation products analysis
Samples for SCFA analysis were randomly selected in each group (n = 6 per group) and were prepared as described (with minor modification) by Wang et al. (35) . Briefly, 30 mg freeze-dried cecum contents were mixed thoroughly with 800 ml doubledistilled H 2 O and 200 ml 50% H 2 SO 4 . After adding 1 ml diethyl ether, the mixture was shaken for 30 min, and the residual water was removed by anhydrous CaCl 2 . The supernatant was collected after centrifugation at 12,000 rpm for 10 min. An aliquot of separated supernatant (1 ml) was used for determining SCFA contents GC-MS (7890B series GC system equipped with 5977A inert MSD system; Agilent Technologies, Santa Clara, CA, USA) coupled with an HP-FFAP column (30 m 3 0.25 mm 3 0.25 mm; Agilent Technologies). The detecting condition was modified slightly according to Etxeberria et al. (36) . Helium was used as the carrier gas at 1 ml/min in nonsplit mode. The initial temperature was 90°C, which was maintained for 1 min, increased to 150°C at 12°C/min, and then raised to 220°C at 20°C/min and maintained for 5 more min. The data were collected in single ion monitoring mode (m/z = 60, 73, and 74). SCFA contents were quantified by external standard method using standard solution mixtures of acetate (Ace), propionate (Pro), and butyrate (Buty).
Gut microbiota analysis
Fecal samples in this assay were randomly selected in each group (n = 6 per group). Bacterial gDNA from feces was extracted using QiaAmp DNA stool Mini Kit (Qiagen, Hilden, Germany), respectively, and monitored on 1% agarose gel for DNA quality qualification. According to the V3-V4 hypervariable region of 16S rRNA genes, universal primers with barcode (338 forward: 59-ACTCCTACGGGAGGCAGCAG-39; 806 reverse: 59-GGAC-TACHVGGGTWTCTAAT-39) were used for amplifying the DNA sequences, followed by generating sequencing libraries using TruSeq DNA PCR-free sample preparation kit (Illumina, San Diego, CA, USA). After assessing the quality, the libraries were sequenced on an Illumina MiSeq platform with 300 bp paired-end reads (Shanghai Majorbio Bio-pharm Technology, Shanghai, China). The sequencing data were submitted to the National Center Of Biotechnology Information Sequence Read Archive Database (https://www.ncbi.nlm.nih.gov/sra) with the accession no. PRJNA513971.
The paired-end reads were merged using fast length adjustment of short reads software (37) . After quality filtering using Trimmomatic software (38) , effective reads were finally obtained by removing the chimera sequences using the UCHIME algorithm (39) . The sequences were aligned into the Silva database of bacterial 16S rRNA genes (https://www.arb-silva.de/) at a 70% confidence level using Usearch software (v.7.0; https:// www.drive5.com/usearch/). The operational taxonomic units (OTUs) were identified as 1 cluster at the 97% similarity level. Subsequently, the rarefaction curve analysis was presented using Mothur software (University of Michigan, Ann Arbor, MI, USA), and a-diversity analysis containing abundance-based coverage estimator and Shannon index was performed (40) . Betadiversity containing principal component analysis (PCA) and principal coordinate analysis (PCoA) with an unweighted-unifrac distance matrix were performed using QIIME (http://qiime.org/). The different relative abundance of bacteria within groups were calculated by Wilcoxon rank-sum test. The linear discriminant analysis (LDA) effect size (LEfSe) was used for selecting biomarkers within different groups at LDA . 4.0 (41) . The cladogram presented significantly changed bacterial taxa within different groups (false discovery rate ,0.05) from the inner to outer rings with phylum, class, order, and family as well as genus. All data were analyzed on the free online platform Majorbio I-Sanger Cloud Platform (www.i-sanger.com).
Phylogenetic reconstruction of unobserved states (PICRUSt) analysis was used for predicting microbial functions with 16S rRNA sequencing (42) . The predicted genes and functions were aligned against the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (https://www.genome.jp/kegg/), and putative pathways were processed (P , 0.001) using MatLab software (2015B; MathWorks, Natick, MA, USA).
Statistical analysis
All data were presented as means 6 SEM. Difference between groups was analyzed by IBM SPSS software (v.20.0; IBM, Armonk NY, USA) using 1-way ANOVA with Tukey's multiple comparison test or Student's t test. A significant difference was considered to be P , 0.05. The results were performed using Prism software (v.7.0; GraphPad Software, La Jolla, CA, USA).
RESULTS
LC beneficially regulates gut microbiota dysbiosis in HFD-fed mice
The gut microbiota has been demonstrated to be a novel superorgan for humans, contributing to maintenance of human physiologic homeostasis (16, 19) . We adopted bacterial 16S rRNA sequencing based on V3-V4 hypervariable regions to analyze the impact of LC supplementation on gut microbiota dysbiosis induced by HFD. With a series of preprocessing (deletion/selection) on original sequences, a total of 1,313,290 effective reads with a mean of 54,720 6 439 reads per mouse was obtained (n = 6) for the subsequent analysis. Rarefaction analysis showed that this sequencing depth covered the rare new phylotypes and the most bacterial diversity (Supplemental Fig. S1A) . The a-diversity analysis containing abundance-based coverage estimator and Shannon index indicated LC supplementation significantly changed the gut microbiota richness and diversity on the OTU level among these 4 groups (Supplemental Fig. S1B ). Moreover, the b-diversity, including PCA and principal coordinate analysis, revealed distinct clusters for each group (NCD, NCD+L, HFD, and HFD+L) in the microbial structure on the OTU level ( Fig. 1A and Supplemental Fig. S1C ), which was consistent with hierarchical clustering tree analysis (Supplemental Fig. S1D ).
As to bacterial composition analysis, LC supplementation, to some extent, regulated bacteria community on various levels (phylum, family, and genus levels as shown in Fig. 1B and Supplemental Fig. S1E ), especially selectively enhancing the proportion of Proteobacteria on the phylum level ( Fig. 1B, right panel) . Although HFD significantly increased the ratio of Firmicutes:Bacteroidetes (P , 0.05; Supplemental Fig. S1F ), LC supplementation did not reverse the Firmicutes:Bacteroidetes ratio in the HFD group (Supplemental Fig. S1F ). On the OTU level, the top 35 different bacterial abundances were shown as a heat map with hierarchical clustering, appropriately separating LC supplementation groups from their own counterparts (Fig. 1C ). Next, we used LEfSe analysis to explore biomarkers presented as taxons in different groups (Fig. 1D,  E) . Compared with the HFD group, LC supplementation significantly decreased the proportion of norank_f_ Bacteroidates_S24-7 group and increased the proportions of Desulfovibrio, Ruminiclostridium_9, Ruminiclostridium, Blautia, and norank_f_Lachnospiraceae (Fig. 1F) . The proportions of Ruminiclostridium_9 and Ruminiclostridium also increased in the NCD+L group compared with its control (Supplemental Fig. S1G ). Additionally, compared with the HFD group, LC supplementation distinctly boosted the abundance of Blautia as representative SCFA-producing bacteria using 16S rRNA sequencing and qRT-PCR analysis (P , 0.05, Fig. 1F, G) . We also verified this conclusion in the in vitro fermentation system using qRT-PCR analysis (P , 0.05; Fig. 1G, right panel) . Consistently, SCFA levels (Ace, Pro, and Buty) in the cecum obviously increased in the HFD+L group compared with the HFD group (P , 0.05, Fig. 1H ).
To figure out the potential function of the gut microbiota within various groups, enriched metabolic pathways from KEGG in each group were predicted by PICRUSt analysis (P , 0.001; Fig. 1I and Supplemental Fig. S1H) . Notably, the distinct enriched metabolic pathway was lipid metabolism, and its proportion was higher in the HFD+L group than the HFD group (Fig. 1I ). We also found LC supplementation might have the potential ability to improve lipid metabolism in the NCD+L group (Supplemental Fig. S1H ). In addition, other metabolic pathways, including purine metabolism, ribosome biogenesis, and protein export, tended to be enriched in the HFD group and decreased in the HFD+L group (Fig. 1I ), suggesting LC supplementation may have broadly changed genetic information processing pathways in the gut microbiome. These results indicated that LC supplementation effectively improved HFD-induced gut microbiota imbalance, promoted SCFA-producing bacteria (e.g., Blautia) abundance, and potentially increased lipid metabolism in the microbiome.
LC restores intestinal barrier damage induced by HFD
Intestinal barrier integrity has been clarified to be of significance for human whole-body health and can be disrupted along with gut microbiota dysbiosis induced by HFD (43) . We observed LC supplementation could recover the damaged enteral barrier in the HFD group using histologic analysis and qRT-PCR assay. As shown in Fig. 2A, B , mice that received LC supplementation possessed longer small intestines than the mice in the HFD group (P , 0.01). To further explore the changes in intestinal morphology, we measured intestinal villi length (P , 0.05) as well as mucus layer thickness (P , 0.01), which all displayed an increasing manner in the HFD+L group (Fig. 2C-F) . Consistently, compared with the HFD group, LC supplementation obviously down-regulated the mRNA expression of tight-junction genes [junctional adhesion molecule-A (JAM-A) and occludin] (P , 0.05) and mucin2 (a gene coding for mucin in the colon) (P , 0.05; Fig. 2G ). These results indicated LC supplementation had an important role in maintaining intestinal epithelium integrity.
LC alleviates obesity and insulin resistance as well as inflammation induced by HFD
To evaluate the effects of LC supplementation on obesity and associated metabolic diseases, we chose obese mice induced by HFD as research model (44) . In comparison with the HFD group, LC supplementation markedly decreased body weight gain (P , 0.001, Fig.  3A ) and energy efficiency (P , 0.05) without affecting energy intake (Fig. 3B, C) . Interestingly, LC supplementation greatly increased TG contents in feces (P , 0.05, Fig. 3D ). Furthermore, compared with the HFD group, LC supplementation did not change body EE either in light phase or in dark phase (Fig. 3E, F) , which was consistent with thermogenic gene expression in various groups (Supplemental Fig. S2 ).
In addition, LC supplementation dramatically suppressed glucose and insulin levels in fasting serum, with a lower homeostatic model assessment for insulin resistance (HOMA-IR) compared with the HFD group (Fig. 3G, H) . We performed ITT and IGTT to demonstrate that LC supplementation significantly enhanced insulin sensitivity in the HFD group (P , 0.01, Fig. 3I,  J) . Then, we assessed the adipose and hepatic mRNA expression of proinflammatory cytokines TNF-a and IL-6 ( Fig. 3K, L) . Beyond that, we still detected MCP-1 expression on the transcriptional level (Fig. 3K, L) as a biomarker for inflammation infiltration of macrophage recruitment (8) . The results showed LC supplementation could distinctly decrease TNF-a and MCP-1 expression in Epi-WAT and liver compared with the HFD group (P , 0.05) but had little effect on IL-6 expression ( Fig. 3K, L) . These findings suggested LC supplementation effectively alleviated obesity and insulin resistance as well as low-grade inflammation.
LC ameliorates lipid metabolic disorder induced by HFD
We separated 4 types of WATs, including Epi-WAT, perirenal (Per)-WAT, mesenteric (Mes)-WAT, and abdominal (Abd)-WAT. Compared with the HFD group, LC supplementation obviously reduced WAT weight (P , 0.01, Fig. 4A ) but had little impacts on brown adipose tissue weight (Fig. 4B ). We observed that LC supplementation distinctly reduced the levels of circulating TG, TC, and free fatty acids in the HFD group (P , 0.05, Fig. 4C, D) . Moreover, H&E staining illustrated LC supplementation effectively inhibited adipocyte enlargement and decreased the mean size of adipose cells by 55.71% (P , 0.01; Fig. 4E, F) . Oil Red O staining indicated LC supplementation significantly alleviated hepatic lipid accumulation (Fig. 4G) and distinctly down-regulated the expression of lipid transport genes [fatty acid binding protein 4 (FABP4) and CD36; P , 0.05] and adipogenesis genes on the transcriptional level [fatty acid synthetase (FAS), P , 0.05] but up-regulated adipolysis genes [peroxisome proliferator-activated receptor (PPAR)-a and PPAR-g coactivator 1 (PGC1) a, P , 0.05] in Epi-WAT (Fig. 4H) . Similarly, as shown in Fig. 4I , compared with the HFD group, LC supplementation dramatically suppressed the hepatic transcriptional expression of lipid transport genes [FABP4, fatty acid transport protein 1 (FATP1), and CD36; P , 0.05] and lipogenesis gens [FAS, sterol regulatory element binding transcriptional factor 1c (SREBP1c), and PPAR-g; P , 0.05]. Interestingly, LC supplementation distinctly increased hepatic stearoyl coenzyme A desaturase 1 (SCD1) expression compared with the HFD group (P , 0.05, Fig. 4I ), whereas it did not change the mRNA expression of lipolysis genes (PPAR-a and PGC1-a) (Fig. 4I) . These findings showed LC supplementation ameliorated lipid accumulation via suppressing lipid synthesis such as SREBP1c-PPARs signaling pathways. As shown in Figs 2-4, LC supplementation had little adverse effects on host phenotypes in the NCD group.
The gut microbiota determines the antiobesity effects of LC
We examined whether the gut microbiota was indispensable for antiobesity roles of LC in artificial germ-free mice treated with AN ( Fig. 5A and Supplemental Fig. S3 ). Under long-term AN treatment, LC supplementation could not increase the abundance of selected representative SCFA-producing Blautia in the HFD group (Fig. 5B) . Consistently, most of the SCFAs in the cecum could not be detected, except low Ace content was similarly found in the HFD+AN group and the HFD+AN+L group ( Supplemental Table S3 ). Compared with the HFD+AN group, LC supplementation did not alter mRNA expression of JAM-A, occludin, and mucin2, which related to intestinal barrier integrity (Fig. 5C ), small intestinal morphology, and colon morphology (Fig. 5D, E) . Moreover, there were no significant differences in body weight gain, energy efficiency, lipid excretion, insulin resistance, and low-grade inflammation between the HFD+AN group and the HFD+AN+L group (Fig. 5F-H) . Given HFD-induced lipid metabolic disorder, under AN treatment, LC supplementation could not distinctly reduce WAT weight and hyperlipidemia (Fig. 5I, J) . Furthermore, LC supplementation could not change adipocyte size and hepatic lipid accumulation in the HFD+AN group and HFD+AN+L group (Fig. 5K, L) . On the transcriptional level, compared with the HFD+AN group, LC supplementation could not alter the mRNA expression of lipid transport genes (FABP4 and CD36), adipogenesis genes (FAS and PPAR-g), and adipolysis genes (PPAR-a and PGC1-a) in Epi-WAT (Fig. 5M) . Similarly, LC supplementation could not alter the hepatic mRNA expression of lipid transport genes (FABP4, FATP1, and CD36), lipogenesis gens (FAS, SCD1, SREBP1c, and PPAR-g), and lipolysis genes (PPAR-a and PGC1-a) in the HFD+AN group (Fig. 5N) . Nevertheless, under long-term AN treatment, we observed that LC supplementation still significantly improved glucose tolerance (P , 0.05; 0.05, Fig. 5J ). These results showed the gut microbiota largely determines antiobesity effects of LC supplementation. 
DISCUSSION
Previous studies reported LC had abundant dietary fibers and beneficial nutrients that displayed antibacterial and hepatic protective roles (31, 45) . However, the antiobesity effects of LC, and whether these effects depended upon the gut microbiota, were unclear. The present work demonstrated that LC could ameliorate overweight gain, excess fat accumulation, and obesity-induced insulin sensitivity as well as inflammation infiltration via maintaining intestinal barrier integrity and surplus lipid excretion. These prevention effects of LC against obesity largely disappeared in AN-treated mice. The data suggested that the gut microbiota largely modulated the beneficial roles of LC in reducing the risk of obesity and associated metabolic syndromes via the interaction between SCFAproducing microbiota and the gut-liver axis (Fig. 6) .
Our results demonstrated that LC selectively displayed an increasing manner in the abundance of phylum Proteobacteria (Fig. 1B) . Several studies have demonstrated Proteobacteria was positively associated with the reduction of metabolic health and adipocyte inflammation (46, 47) . However, there are certain controversies on the correlation between Proteobacteria and physiologic balance. Several studies reported that gut dysbiosis and metabolic syndromes increased the abundance of Proteobacteria in the intestinal microbiome from animal models or humans (19, 48, 49) . In view of gut microbiota composition on the genus level, LC raised the abundance of Ruminiclostridium_9 and Ruminiclostridium ( Fig. 1F and Supplemental Fig. S1G ), which may be associated with cellulose degradation (50) ; specific mechanisms still need to be investigated in the future. Additionally, we still found that LC also selectively increased the sulfatereducing bacteria Desulfovibrio ( Fig. 1F and Supplemental Fig. S1G ), indicating the existence of complex metabolism in the enteral microbiome. Gut barrier integrity provided a defense line against unhealthy substances derived from the exogenous environment (51) . SCFAs are the end products fermented from dietary fiber or polysaccharide by certain gut bacteria that improve host physiologic disorders, such as enteral homeostasis dysbiosis, abnormal lipid metabolism, and active immune response (23, 26, 44) . Specifically, Buty served as energy resource for colonic integrity, and Ace as well as Pro could be absorbed by peripheral organs to benefit host health (19) . In basic nutritional compositions, the freeze-dried whole fruit of LC possessed 20.74% dietary fiber (Supplemental Table S1 ). The present work revealed that LC effectively generated more SCFAs (Ace, Pro, and Buty) and improved enteral homeostasis ( Figs. 1 and 2) . Previous studies showed genus Blautia was identified to produce SCFAs and was positively correlated with metabolic homeostasis improvement after prebiotic intervention (52) (53) (54) . Consistently, in gut microbiota with high abundance, we observed LC remarkably boosted representative SCFA-producing bacteria Blautia in HFD groups in in vivo and in vitro systems (Fig. 1F, G) , along with enhanced SCFA levels in the cecum (Fig. 1H) , indicating that LC maintained the stable intestinal homeostasis via promoting the beneficial gut bacteria. PICRUSt analysis suggested that LC potentially tended to mediate lipid metabolism in the intestinal microbiome ( Fig. 1I and Supplemental Fig. S1H ), which was in accordance with high-TG elimination (Fig. 3D ). As is known, lipid metabolism is closely linked to bacterial deconjugation of bile acids derived from the liver (55), and Blautia was demonstrated to be involved in bile transformation and gastrointestinal function (56, 57) . Furthermore, we used an antibiotic mixture to delete the gut microbiome and demonstrated that LC could not change Blautia abundance under AN treatment (Fig. 5B) , which was much lower than Figure 6 . Speculative mechanism of the gut microbiota for mediating the beneficial effects of LC against obesity via microbiotagut-liver axis. SCFA-producing bacteria fermented LC to generate SCFAs for maintaining gut barrier integrity, which assist in surplus TG excretion and suppress hepatic lipid synthesis (SREBP1c-PPAR-g) and low-grade inflammation, further alleviating the development of obesity with associated metabolic syndromes.
the abundances in HFD and HFD+L groups (Fig. 1G) , as supported by little detectable SCFAs contents in cecum ( Supplemental Table S3 ). Thus, the gut microbiota determines the antiobesity effects of LC, which may be due to abundant dietary fiber in LC. Moreover, the gut microbiota, especially SCFA-producing bacteria (e.g., Blautia), determined the protective roles of LC against diet-induced obesity. This is in accordance with a previous study that bitter melon could improve metabolic disorders and dramatically increase the abundance of Blautia under HFD treatment (54) .
The process of lipid transportation usually assisted fatty acids in entering into the cell for providing substrates for lipid synthesis. SREBP1c was a membranebound transcriptional factor and was further up-regulated key enzymes in sterol biosynthesis (58) . Meanwhile, PPAR-g , as a nuclear receptor, also participated in lipid biosynthesis (59) . Apart from improving gut microbiota dysbiosis, LC dramatically reduced the transcriptional expression of key genes in lipid transport (FABP4, FATP1, and CD36) and lipid synthesis (FAS, SREBP1c, and PPAR-g) (Fig. 4H, I) for inhibiting hepatic lipid deposition (Fig. 4G ). Previous studies indicated SCD1 was responsible for catalyzing saturated fatty acid (SFA) into less-lipotoxic monounsaturated fatty acid (60) , and SCD1 deficiency could alleviate obesity and associated insulin resistance (61) . Interestingly, we observed LC up-regulated the mRNA expression of SCD1 in the HFD group (Fig. 4I ). It can be speculated that the HFD disturbed the balance between SFA and monounsaturated fatty acid in liver but LC supplementation may reduce high lipotoxic SFA concentration via increasing SCD1 expression and further suppressing low-grade inflammation (Fig. 3L ). Another reason may be due to compensatory gene expression in the complex metabolic network that responds to LC administration. However, we still need to confirm this hypothesis using protein expression assay and hepatic high-precision metabolome analysis in future. In addition, we observed LC could only obviously up-regulate the adipocyte transcriptional expression of PPAR-a and PGC1-a, which are involved in lipid oxidation (Fig. 4H, I) , indicating LC could assist excessive lipids by oxidizing in WAT rather than liver. Nevertheless, LC could not raise thermogenic gene expression [uncoupling protein 1 and PR domain containing 16 (PRDM16)] in adipocytes (Supplemental Fig. S2 ). Uncoupling protein 1 and PRDM16, as thermogenic genes for beige adipocytes in WAT, produced heat and contributed to systemic EE (62-64). Consistently, LC did not increase the whole-body EE (Fig. 3E,  F) . It is suggested that LC inhibited obesity and fat accumulation through suppressing hepatic lipid synthesis (SREBP1c-PPAR-g signaling pathways). In addition, dramatic reduction of the gut microbiota was largely deprived of the antiobesity effects of LC in the whole-body phenotype, organ morphology, and transcriptional expression ( Fig. 5 ). Nevertheless, LC could still slightly improve glucose tolerance, low-grade inflammation, and hyperlipidemia with the deletion of intestinal microbiota (Fig. 5G-J) . Therefore, the antiobesity effects of LC may result from the synergistic roles of dietary fiber and various phytochemicals (phenolic compounds, saponin, or triterpenoid). Hence, the microbiota-gut-liver axis was supposed to exist in the prevention effects of LC against obesity ( Fig.  6 ), which was supported by a high abundance of Blautia (Fig. 1F, G) and more hepatic gene expression in response to LC supplementation in HFD-fed mice (Fig.  4H, I) .
In summary, the gut microbiota was responsible for antiobesity effects of LC. Combining high-throughput sequencing with phenotype comparison analysis, the present study indicates that LC relieves obesity and associated metabolic syndromes via enhancing SCFAproducing bacteria (e.g., Blautia) and maintaining enteral barrier integrity for increasing unhealthy substance elimination ( Fig. 6 ). Based on the results mentioned above, it is meaningful to identify the specific bioactive components responsible for LC that targeted the microbiota-gut-liver axis to reduce obesity risk. Vegetables are essential to the human diet because of their abundant dietary fibers and nutrition with low calories. Our findings suggest longterm administration of LC is safe and beneficial and can be potentially used in dietary strategies and nutritional guidance for targeting the gut microbiota against obesity and enteral homeostasis.
